XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenue    
Research grants and contracts $ 2,686,042 $ 294,633
License revenue 4,938 4,938
Total revenue 2,690,980 299,571
Operating expenses    
Research and development 5,746,971 2,786,122
General and administrative 2,447,894 2,030,516
Goodwill impairment charges 490,676  
Total operating expenses 8,685,541 4,816,638
Loss from operations (5,994,561) (4,517,067)
Other income (expense)    
Changes in fair value of warrant liability 1,547,982  
Changes in fair value of embedded derivative (7,042)  
Interest expense (870) (60,603)
Interest income 31,590  
Other income (expense), net 257,725 (1,111)
Total other income (expense), net 1,829,385 (61,714)
Net loss before income tax benefit (4,165,176) (4,578,781)
Income tax benefit 991,638  
Net loss (3,173,538) (4,578,781)
Other comprehensive income - foreign currency translation adjustments 615,471 579,836
Comprehensive loss (2,558,067) (3,998,945)
Net loss (3,173,538) (4,578,781)
Preferred stock accretion and dividends (1,891,321) (118,356)
Net loss attributable to common stockholders $ (5,064,859) $ (4,697,137)
Weighted-average common shares outstanding, basic and diluted 20,145,270 6,917,708
Net loss per share attributable to common stockholders, basic and diluted $ (0.25) $ (0.68)